Related Experiment Videos
Bone marrow transplantation for sickle cell anemia
1Department of Pediatric Hematology, Cliniques Saint Luc, University of Louvain, Brussels, Belgium.
Current Opinion in Hematology
|March 1, 1996
Summary
Bone marrow transplantation is a leading therapy for thalassemia major and effective for sickle cell anemia. Patient selection for this treatment requires careful consideration of various factors due to disease variability.
Area of Science:
- Hematology
- Transplantation Medicine
- Genetic Disorders
Background:
- Bone marrow transplantation (BMT) is a primary treatment for thalassemia major in eligible young patients.
- While effective for sickle cell anemia, BMT enthusiasm is tempered by the disease's unpredictable nature.
- Establishing consistent patient selection criteria for BMT in hemoglobinopathies remains challenging.
Purpose of the Study:
- To summarize key factors influencing the decision-making process for bone marrow transplantation in hemoglobinopathies.
- To highlight the complexities in selecting appropriate candidates for BMT, considering disease and patient-specific variables.
Main Methods:
- Review of factors influencing BMT decisions for hemoglobinopathies.
- Discussion of genetic, environmental, and patient-related criteria.
- Consideration of alternative therapeutic approaches.
Main Results:
- Thalassemia major patients with suitable donors are candidates for BMT.
- Sickle cell anemia treatment with BMT is effective but limited by disease unpredictability.
- Selection criteria involve patient age, organ damage, genetic/environmental factors, and alternative therapies.
Conclusions:
- Bone marrow transplantation is a crucial therapy for certain hemoglobinopathies.
- Careful patient selection is paramount for successful BMT outcomes.
- Ongoing research into alternative treatments may influence future BMT decisions.